Neratinib Maleate Clinical Trials

2 actively recruiting trials across 1 location

Also known as: 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1), HKI-272 Maleate, NERATINIB MALEATE ANHYDROUS, Nerlynx

Pipeline

Phase 2: 2

Top Sponsors

National Cancer Institute (NCI)2

Indications

Recurrent Malignant Female Reproductive System Neoplasm2
Malignant Female Reproductive System Neoplasm2
Recurrent Malignant Solid Neoplasm2
Cancer2
Unresectable HER2-Negative Breast Carcinoma1

Birmingham, Alabama2 trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

University of Alabama at Birmingham Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.